Conclusion
Based on the analysis above, we can conclude that:
• Stock risk of Indofarma is 5,259%, means that the company market has chance to loss 5,259%and gain 5,259%.
• Market risk of Indofarma is 2, 1897% means that the company market has chance to loss 2, 1897% and gain 2, 1897%.
• Compare to stock return and market return we can conclude that the risk of stock is higher than the market risk. It means that if we invest in the Indofarma it is non profitable.
• Beta of company stock is 0,128644203, means that beta less than 1. Stocks with a beta less than 1 have less price volatility than the market as a whole and are considered to have less risk.
• Based on portfolio analysis:
We can see that Indofarma has two Strategic Business Unit which are PT Indofarma Global Medika (perusahaan distribusi) and PT Riasima Apotek Farmasi. But from analysis above we can see that these two business unit have a problem as result there is huge loss, so the government has plan two merge these two business unit to increase the company performance and profit.
From product aspect, we can see that generic medicine is leader of this business, and the net sales give good result for the company.

RISK MANAGEMENT IN BCA

Summary

- Running business also faces some risk

- In BCA that running on banking there many risk and they classified into 8 main risks

- Good handling of risk by BCA is proven by the quality on its service, rate on interest and also the power of the bank

- BCA realized that human resources must be developing through some training program so they can handle and dealing with the risks especially in bad economic condition like now

-BCA build committee to support risk management in BCA

Hello world!

Welcome to WordPress.com. This is your first post. Edit or delete it and start blogging!